Management and survival rates for malignant pleural effusions at Tishreen University Hospital
Abstract
Introduction: Malignant pleural effusion is defined as an effusion containing neoplastic cells. It is most common in metastatic tumors and it causes dyspnea, cough and chest pain. Prognosis varies depending on the location and stage of the primary tumor, the patient's clinical condition, age, and other factors. As a result of this difference and because of the large number of malignancies leading to malignant effusions; it is difficult to predict the prognosis or survival rates of these patients. Therefore, following them in terms of these rates and their correlation with aforementioned factors enables us to draw results that serve future research related to diagnostic and therapeutic methods and warning of this group.
Research methods: We conducted a study on patients with malignant and semi-malignant pleural effusions in Tishreen University Hospital between the beginning of January and the end of June of 2020, and then followed them up for a whole year. The patients' gender, age, the type of the primary tumor and its histological pattern were recorded. Patients were also classified according to whether they had undergone thoracentesis or pleural biopsy, the results of the cytological study of the pleural fluid when it was performed, the side of the effusion and finally whether patients undergone pleurodesis or didn’t. The survival time was calculated from the diagnosis of pleural effusion until death or the passing of a year; whichever happened first. The final patient population was 89.
Results: Male patients predominated our study group, and so did the patients that are younger than 60 years. Lung tumors were the most common cause of effusion (28.1%), followed by hematological tumors and metastases of unknown origin. Histologically, adenocarcinoma occupied the largest percentage (28.1%), followed by non-Hodgkin's lymphoma and squamous cell carcinoma. Finally, pleurodesis was performed in 23.6% of the sample.
Survival rates did not differ significantly between males and females, nor between the two age groups. None of the primary tumors was associated with a significant effect on survival rates. The effect of adenocarcinoma on survival rates was statistically (P < 0.001) and clinically significant; greatly reducing these rates. Finally, pleurodesis was a statistically significant factor (P = 0.04) in improving survival rates.
Conclusions: Malignant pleural effusion is associated with low survival rates. Lung tumors are the most common cause of this effusion. Adenocarcinoma is the most common histological pattern, and it is of great statistical importance in reducing the survival rates of patients with malignant pleural effusion. Finally, pleurodesis was associated with significantly better survival rates.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The authors retain the copyright and grant the right to publish in the magazine for the first time with the transfer of the commercial right to Tishreen University Journal for Research and Scientific Studies - Health Sciences Series
Under a CC BY- NC-SA 04 license that allows others to share the work with of the work's authorship and initial publication in this journal. Authors can use a copy of their articles in their scientific activity, and on their scientific websites, provided that the place of publication is indicted in Tishreen University Journal for Research and Scientific Studies - Health Sciences Series . The Readers have the right to send, print and subscribe to the initial version of the article, and the title of Tishreen University Journal for Research and Scientific Studies - Health Sciences Series Publisher
journal uses a CC BY-NC-SA license which mean
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
- The licensor cannot revoke these freedoms as long as you follow the license terms.
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
- ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.